[TS-1 therapy for advanced gastric cancer].
Kurihara
M
M
Department of Gastroenterology, Toyosu Hospital, Showa University.
Koizumi
W
W
Hasegawa
K
K
Sakata
Y
Y
Ohtsu
A
A
Taguchi
T
T
D000284:Administration, Oral; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D017322:Clinical Trials, Phase II as Topic; D042943:Dihydrouracil Dehydrogenase (NADP); D004338:Drug Combinations; D006801:Humans; D010088:Oxidoreductases / Q000037:antagonists & inhibitors; D010094:Oxonic Acid / Q000008:administration & dosage / Q000009:adverse effects; D011725:Pyridines / Q000008:administration & dosage / Q000009:adverse effects; D013274:Stomach Neoplasms / Q000188:drug therapy*; D005641:Tegafur / Q000008:administration & dosage / Q000009:adverse effects; D016896:Treatment Outcome
D004338:Drug Combinations; D011725:Pyridines; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid; D010088:Oxidoreductases; D042943:Dihydrouracil Dehydrogenase (NADP)